Hummingbird Bioscience has a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. The company has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins their passion to accelerate the journey of new drugs from concept to clinic.